--- title: "Nuvectis Pharma (NVCT) news: offering" url: "https://aibio.space/companies/nuvectis-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NVCT offering news: Nuvectis Pharma sets up $60 million at-the-market stock program with Leerink. Nuvectis Pharma, Inc. (NASDAQ: NVCT), United States." --- NVCT Nuvectis Pharma, Inc. NASDAQ · United States # Nuvectis Pharma (NVCT) news NVCT offering news Financings · 2025-05-09 ## [Nuvectis Pharma sets up $60 million at-the-market stock program with Leerink](https://aibio.space/news/nuvectis-pharma-sets-up-60-million-market-stock-program-leerink/) Nuvectis can sell up to $60 million of stock through Leerink. It ended an earlier $40 million program with H.C. Wainwright after selling about $18.6 million under it. ## Latest Nuvectis Pharma news We have not published a story on Nuvectis Pharma yet. When there is news, it will appear here. ## Nuvectis Pharma at a glance - **Ticker**: NVCT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $22.2 million ### Related companies - [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) NASDAQ: ATYR - [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) OTC: NWBO - [Vericel](https://aibio.space/companies/vericel/) NASDAQ: VCEL - [Genprex](https://aibio.space/companies/genprex/) NASDAQ: GNPX - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) NASDAQ: PHAT - [Matinas Biopharma Holdings](https://aibio.space/companies/matinas-biopharma/) AMEX: MTNB - [Citius Oncology](https://aibio.space/companies/citius-oncology/) NASDAQ: CTOR ### Also on NASDAQ - [Sarepta Therapeutics](https://aibio.space/companies/sarepta-therapeutics/) SRPT - [Jupiter Neurosciences](https://aibio.space/companies/jupiter-neurosciences/) JUNS - [Tempus AI](https://aibio.space/companies/tempus-ai/) TEM - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NIKI - [RAPID MICRO BIOSYSTEMS, INC.](https://aibio.space/companies/rapid-micro-biosystems/) RPID - [IRulya Therapeutics](https://aibio.space/companies/irulya-therapeutics/) IRLA ## What Nuvectis Pharma does Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead product candidate, NXP900, is a targeted small molecule that inhibits the SRC and YES1 kinases, which the company says it licensed worldwide commercial rights to in August 2021 from the University of Edinburgh. The FDA cleared the Investigational New Drug application for NXP900 in May 2023, with a Phase 1 protocol in two parts: a dose-escalation Phase 1a and an expansion Phase 1b. In July 2025 the company completed the Phase 1a part, in which a dose range of 20 to 300 mg/day was evaluated and the dose-limiting toxicity level was not reached. A pharmacodynamic response of approximately 90% inhibition of SRC kinase phosphorylation was seen at doses of 150 mg/day and higher. The Phase 1b expansion began in August 2025 and will evaluate NXP900 as a single agent in specific tumor types and in combination with EGFR and ALK inhibitors. The company's text notes SRC is aberrantly activated in breast, colon, prostate, pancreatic and ovarian cancers and that no FDA-approved selective YES1 inhibitor exists. | Product or program | What it is | Stage | |---|---|---| | NXP900 | Targeted small molecule inhibiting SRC and YES1 kinases for solid tumors | Phase 1b expansion initiated August 2025 | Summarised from the company's [10-K filed Feb 11, 2026](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm). ## Nuvectis Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$18.2 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | [$12.9 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | | Net income (loss) | [-$26.4 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | [-$19.0 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | | Cash from operations | [-$16.0 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | [-$12.2 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | | Cash and equivalents | [$31.6 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926090109/) | [$18.5 million](https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $22.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Mixed view 2026-10-28 [Nuvectis has the cash for now, but its trials will need more money](https://aibio.space/analysis/nuvectis-has-cash-now-but-trials-will-need-more-money/) A July offering added about $106.3 million net, and $20.0 million of it went to Haisco for two more early drugs. The company says it can fund planned operations for at least 12 months, and that it needs more money to finish its trials. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Nuvectis Pharma Has Nuvectis Pharma raised money recently? Our latest story on this, dated May 9, 2025: "Nuvectis Pharma sets up $60 million at-the-market stock program with Leerink". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nuvectis-pharma-sets-up-60-million-market-stock-program-leerink/). What is the ticker symbol of Nuvectis Pharma? Nuvectis Pharma, Inc. trades under the ticker NVCT on NASDAQ. Where is Nuvectis Pharma listed? Nuvectis Pharma, Inc. is listed on NASDAQ. What is the SEC CIK of Nuvectis Pharma? The SEC Central Index Key (CIK) for Nuvectis Pharma, Inc. is 1875558. Its filings are on SEC EDGAR. How many shares does Nuvectis Pharma have outstanding? 32,581,533 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Nuvectis Pharma listed under? Our directory records Nuvectis Pharma, Inc. under United States. What does Nuvectis Pharma do? Our directory classifies Nuvectis Pharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Nuvectis Pharma? The ISIN recorded for Nuvectis Pharma, Inc. is US67080T1088. Does aibio.space cover Nuvectis Pharma? aibio.space lists Nuvectis Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nuvectis Pharma incorporated? SEC records list its state or country of incorporation as DE. What does Nuvectis Pharma develop? Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead product candidate, NXP900, is a targeted small molecule that inhibits the SRC and YES1 kinases, which the company says it licensed worldwide commercial rights to in August 2021 from the University of Edinburgh. What is NXP900 from Nuvectis Pharma? NXP900: Targeted small molecule inhibiting SRC and YES1 kinases for solid tumors Stage: Phase 1b expansion initiated August 2025. Is Nuvectis Pharma profitable? Nuvectis Pharma, Inc. reported a net loss of $26.4 million for the fiscal year ended Dec 31, 2025, and used $16.0 million of cash in operations, per its annual report to the SEC. How much does Nuvectis Pharma spend on research and development? $18.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Nuvectis Pharma have? $22.2 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Nuvectis Pharma Members talk about Nuvectis Pharma (NVCT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nuvectis Pharma, newest first. Each line links the filing it comes from. 1. 2026-08-21 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1875558/000110465926099712/tm2623689d1_8k.htm) 2. 2026-06-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1875558/000110465926078864/tm2618981d1_424b5.htm) 3. 2026-02-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1875558/000110465926015159/tm266190d1_s3.htm) 4. 2025-05-09 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1875558/000110465925046838/tm2514403d1_424b5.htm) 5. 2025-02-04 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1875558/000110465925009141/tm255282d1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NVCT on TradingView](https://www.tradingview.com/symbols/NASDAQ-NVCT/). ## SEC filings and registration - **SEC name**: Nuvectis Pharma, Inc. - **CIK**: 1875558 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NVCT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024 - **Phone**: 360-837-7232 - **Shares outstanding**: 32,581,533 as of 2026-07-31 (10-Q filed 2026-08-04) ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1875558/000110465926099717/tm2623146d1_s3.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1875558/000110465926099712/tm2623689d1_8k.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1875558/000110465926090109/tmb-20260630x10q.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_8k.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1875558/000110465926079360/tm2619346d1_8k.htm) filed 2026-06-30 - [424B5](https://www.sec.gov/Archives/edgar/data/1875558/000110465926079359/tm2618981d3_424b5.htm) filed 2026-06-30 - [424B5](https://www.sec.gov/Archives/edgar/data/1875558/000110465926078864/tm2618981d1_424b5.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/tm2618981d2_8k.htm) filed 2026-06-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001875558), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nuvectis Pharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NVCT, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nuvectis Pharma, Inc. - **Ticker**: NVCT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US67080T1088 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NVCT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nuvectis-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nuvectis Pharma (NVCT) news: offering", 2026-10-31, https://aibio.space/companies/nuvectis-pharma/